# LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Source: https://onco.cc/trials/nct02159066/  
OnCo record `nct02159066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Infigratinib and Capmatinib in Melanoma, run by Pfizer, completed.

## Summary

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma is a phase 2 interventional study registered as NCT02159066 by Pfizer, with 158 participants recorded, started 2014-07-23 and reaching its primary completion in 2023-01-10. Interventions recorded: LGX818, MEK162, LEE011, BGJ398, BKM120, INC280. Conditions recorded: Melanoma.

Linked to the drug Infigratinib because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-24
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02159066
- Phase: 2
- Setting: The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.
- Sponsor: Pfizer
- Enrolled: 158
- Outcomes: Overall Response Rate (ORR): Part II: Part II: Encorafenib + Binimetinib + Ribociclib 2.6% vs Part II: Encorafenib + Binimetinib + Infigratinib 0% vs Part II: Encorafenib + Binimetinib + Capmatinib 0% vs Part II: Encorafenib + Binimetinib + Buparlisib 0%; Overall Survival (OS): Part II: Part II: Encorafenib + Binimetinib + Ribociclib 10.4 months vs Part II: Encorafenib + Binimetinib + Infigratinib 20.8 months vs Part II: Encorafenib + Binimetinib + Capmatinib 5.6 months vs Part II: Encorafenib + Binimetinib + Buparlisib 2.5 months; Progression-Free Survival (PFS): Part I: Part I: Encorafenib + Binimetinib (Naive) 11.1 months vs Part I: Encorafenib + Binimetinib (Non-naive) 3.3 months

## Sources

- ClinicalTrials.gov NCT02159066: https://clinicaltrials.gov/study/NCT02159066

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Capmatinib](https://onco.cc/drugs/capmatinib/), [Infigratinib](https://onco.cc/drugs/infigratinib/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct02159066.json